Illumina partners with Veritas Genetics to advance preventive genomics

New collaboration aims to bring population-scale whole-genome sequencing into everyday healthcare, enabling earlier risk detection and data-driven prevention.

Mar. 16, 2026 at 6:15pm

Got story updates? Submit your updates here. ›

Illumina, Inc. has announced a strategic collaboration with Veritas Genetics Powered By Fuze Health to form a consortium that aims to bring preventive genomics into everyday healthcare through health insurance plans in the United States and under other global markets. The collaboration supports an integrated data ecosystem to advance research, drug discovery, and clinical trial optimization by combining clinical-grade sequencing, advanced informatics, and member-ready reporting.

Why it matters

Genomics is increasingly moving upstream in healthcare, from diagnosing disease to helping prevent it. By combining Illumina's sequencing and informatics backbone with Veritas' patient-ready reporting, this collaboration represents an important step forward in making preventive genomics actionable, accessible, and integrated into everyday healthcare.

The details

The consortium is designed to provide an opt-in preventive genomics program that delivers actionable genomic insights and connects those insights to appropriate interventions, integrated care pathways for actionable findings, a streamlined member experience, and a consented, integrated clinical-genomics dataset to enable industry partnerships across precision medicine. Veritas has elected to build and validate workflows based on Illumina sequencing and informatics technologies, while Veritas will provide the experience layer, including interpretation capabilities with myGenome reporting, clinical interpretation, and access to genetic counseling services.

  • The collaboration was announced on March 16, 2026.

The players

Illumina, Inc.

A global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical, and applied markets.

Veritas Genetics Powered By Fuze Health

A leader in clinical genomics, offering advanced human-genome sequencing and interpretation services to enable accurate diagnosis, personalized prevention, and improved healthcare decision-making.

Rami Mehio

General manager, BioInsight at Illumina.

Javier de Echevarría

CEO of Veritas Genetics and Chief Genomics Officer of Fuze Health.

Got photos? Submit your photos here. ›

What they’re saying

“Genomics is increasingly moving upstream in healthcare, from diagnosing disease to helping prevent it. By combining Illumina's sequencing and informatics backbone with Veritas' patient-ready reporting, this collaboration represents an important step forward in making preventive genomics actionable, accessible, and integrated into everyday healthcare.”

— Rami Mehio, General manager, BioInsight at Illumina (morningstar.com)

“The myGenome whole-genome sequencing comprehensive genetic risk service has been developed to integrate into a health insurer's environment and enable members to benefit from preventive genomics at a personalized level.”

— Javier de Echevarría, CEO of Veritas Genetics and Chief Genomics Officer of Fuze Health (morningstar.com)

What’s next

The collaboration is structured around distinct but complementary roles, where Veritas has elected to build and validate workflows based on Illumina sequencing and informatics technologies, while Veritas will provide the experience layer, including interpretation capabilities with myGenome reporting, clinical interpretation, and access to genetic counseling services.

The takeaway

This collaboration between Illumina and Veritas Genetics represents a significant step forward in making preventive genomics more accessible and integrated into everyday healthcare, empowering individuals to proactively leverage whole-genome data to support earlier identification of disease risk and more personalized prevention strategies.